Individualized treatment rules: generating candidate clinical trials.
Individualized treatment rules, or rules for altering treatments over time in response to changes in individual covariates, are of primary importance in the practice of clinical medicine. Several statistical methods aim to estimate the rule, termed an optimal dynamic treatment regime, which will result in the best expected outcome in a population. In this article, we discuss estimation of an alternative type of dynamic regime-the statically optimal treatment rule. History-adjusted marginal structural models (HA-MSM) estimate individualized treatment rules that assign, at each time point, the first action of the future static treatment plan that optimizes expected outcome given a patient's covariates. However, as we discuss here, HA-MSM-derived rules can depend on the way in which treatment was assigned in the data from which the rules were derived. We discuss the conditions sufficient for treatment rules identified by HA-MSM to be statically optimal, or in other words, to select the optimal future static treatment plan at each time point, regardless of the way in which past treatment was assigned. The resulting treatment rules form appropriate candidates for evaluation using randomized controlled trials. We demonstrate that a history-adjusted individualized treatment rule is statically optimal if it depends on a set of covariates that are sufficient to control for confounding of the effect of past treatment history on outcome. Methods and results are illustrated using an example drawn from the antiretroviral treatment of patients infected with HIV. Specifically, we focus on rules for deciding when to modify the treatment of patients infected with resistant virus.
Petersen
Maya L
ML
Division of Biostatistics, University of California, School of Public Health, Earl Warren Hall #7360, Berkeley, CA 94720-7360, U.S.A. mayaliv@berkeley.edu
Deeks
Steven G
SG
van der Laan
Mark J
MJ
D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic / Q000379:methods*; D004334:Drug Administration Schedule; D006678:HIV / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D015233:Models, Statistical; D012367:RNA, Viral / Q000097:blood; D012107:Research Design
D044966:Anti-Retroviral Agents; D012367:RNA, Viral